Using Serological Proteome Analysis to Identify and Evaluate Anti-GRP78 Autoantibody as Biomarker in the Detection of Gastric Cancer

Table 2

The performance of anti-GRP78 antibody in the subgroup analysis.

Clinical characteristics		AUC	95% CI	Se (%)	Sp (%)	+LR	−LR	Youden’s index
Test cohort
TNM	Early-stage (I-II)	0.725	0.625 to 0.824	40.54	91.73	4.90	0.65	0.323
	Late-sage (III-IV)	0.720	0.642 to 0.798	40.30	91.73	4.87	0.65	0.320
Differentiation degree	Poor	0.686	0.591 to 0.781	37.78	91.73	4.57	0.68	0.295
	Moderate and high	0.742	0.623 to 0.860	44.00	90.23	4.50	0.62	0.342
LM	LM	0.721	0.644 to 0.799	42.65	90.23	4.36	0.64	0.329
	No LM	0.700	0.583 to 0.816	42.42	91.73	5.13	0.63	0.342
Tumor size	<5 cm	0.676	0.583 to 0.769	29.17	96.99	2.98	0.73	0.262
	≥5 cm	0.773	0.679 to 0.867	55.56	90.23	5.68	0.49	0.458
GC vs. NH		0.718	0.657 to 0.779	43.61	90.23	4.46	0.62	0.338
Validation cohort
TNM	Early-stage (I-II)	0.648	0.585 to 0.712	33.04	90.30	3.41	0.74	0.233
	Late-sage (III-IV)	0.645	0.579 to 0.711	33.33	90.97	3.69	0.73	0.243
Differentiation degree	Poor	0.671	0.606 to 0.735	34.23	90.97	3.79	0.72	0.252
	Moderate and high	0.664	0.605 to 0.724	37.41	90.30	3.86	0.69	0.277
LM	LM	0.650	0.590 to 0.709	35.51	90.30	3.66	0.71	0.258
	No LM	0.690	0.620 to 0.760	36.14	93.31	5.40	0.68	0.295
Tumor size	<5 cm	0.707	0.635 to 0.779	37.66	90.97	4.17	0.69	0.286
	≥5 cm	0.656	0.573 to 0.740	38.03	92.98	5.41	0.67	0.310
GC vs. NH		0.666	0.623 to 0.710	35.33	90.30	3.64	0.72	0.256

LM: lymphatic metastasis; Se: sensitivity; Sp: specificity; +LR: positive likelihood ratio; −LR: negative likelihood ratio.